Prellis Biologics, a San Francisco, CA-based biotherapeutics company, raised $35M in Series C funding.
The round, which brings funding to date to $64.5m, was led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group.
The company intends to use the funds to expand its proprietary, first-in-class human immune system-based drug discovery and development platform, EXIS™ (Externalized Human Immune System).
Led by CEO Michael Nohaile, Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. Prellis’ proprietary platform Externalized Immune System, EXIS™, precisely reproduces the human immune response through the creation of lymph node organoids (LNOs). With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications including antibody discovery, immunogenicity assessment and tumor-immune models.
Dr. Nohaile joins from Generate Biomedicines and succeeds Prellis Bio founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a Board seat. The company will also add two new board members: Lei Meng, Senior Therapeutics Analyst of Avidity Partners, and Nobel Prize winner James Rothman, PhD the Sterling Professor of Cell Biology at Yale University.
Earlier this year, Prellis Bio announced collaboration and licensing option agreements with Sanofi and Bristol Myers Squibb.
FinSMEs
10/08/2022